Nasdaq
$54.00▲ 1.89%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.74BShares out 69.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 10.14Pre-market26.10.14 21:438-KKey event#●●●#●●●#●●●
PULSE BIOSCIENCES, INC.Bullish
Pulse Biosciences has entered into a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Under this agreement, the center will utilize the company's nPulse Vybrance Percutaneous Electrode System for patient treatment, while both parties will collaborate to collect clinical data and conduct studies on the use of nsPFA energy for treating benign thyroid nodules.…more
$54.00+1.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7Pre-market26.10.07 22:068-KKey event
PULSE BIOSCIENCES, INC.
Pulse Biosciences has achieved its target enrollment of 164 evaluable patients for the NANOPULSE-AF clinical study of its nPulse Cardiac Catheter System for atrial fibrillation. The enrollment was completed three months ahead of the original nine-month timeline, and the company will now assess safety and effectiveness endpoints at 6 and 12 months post-ablation.…more
$54.00+1.89%vs prev closeView filingShare - 9.15After-hours26.09.16 05:448-KKey event
PULSE BIOSCIENCES, INC.
Pulse Biosciences has entered into a new equity distribution agreement with Mizuho Securities to offer and sell up to $85 million in common stock. Concurrently, the company terminated its prior distribution agreement with TD Cowen, noting that 1,379,925 shares were sold for approximately $68.8 million under the previous August 2026 agreement. This move represents a strategic shift in the company's capital-raising activities.…more
$54.00+1.89%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 20:06#●●●#●●●
Pulse Biosciences Announces Partnership with Clayman Thyroid Center
Pulse Biosciences has partnered with the Clayman Thyroid Center to implement its nPulse Vybrance System for patient care. The collaboration aims to support commercial use while generating additional clinical data on the use of nsPFA technology for benign thyroid nodules.…more
$54.00+1.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.7Pre-market26.10.07 20:07
●●●●●●●● ●●●●● ●●●●●●
Pulse Biosciences has finished enrolling 164 patients for its pivotal atrial fibrillation study three months earlier than planned. This accelerated timeline marks a significant milestone in the company's clinical development process for the nPulse catheter.…more
$54.00+1.89%vs prev closeShareBenzinga - 9.15After-hours26.09.16 05:52
●●●●●●●● ●●●●● ●●●●●●
Pulse Biosciences has entered into an agreement to sell up to $85 million in common stock through an at-the-market offering via Mizuho Securities. This move introduces potential equity dilution for existing shareholders.…more
$54.00+1.89%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report